- Relocation to Support Drug Discovery Paradigm and Expansion of Staff -
- New Haven Mayor John DeStefano, Jr to Attend Opening Celebration -

New Haven, Connecticut, September 9, 2002 - Rib-X Pharmaceuticals, Inc., a privately held bioscience company focused on the discovery of new anti-infectives, today announced the relocation of the company's corporate headquarters and research operations to a new facility in The George Street Technology Center, located at 300 George Street in New Haven. Mayor John DeStefano, Jr is expected to attend the opening celebration, which will be held at the new facility on Tuesday, September 10, 2002 from 4pm-6pm (EDT).

"The design of the new space allows us to implement our integrated, structure-based drug design approach by bringing biochemistry, microbiology, crystallography, computation and chemistry together to form the optimal drug discovery environment " said Dr. Susan Froshauer, the President and CEO of Rib-X. "As we move towards the clinical process, Rib-X is in a heavy growth mode. We have hired more than 40 people during the past year, with plans for at least 20 more by year's end. Our expansion is fueling the development of a true heterogeneous community as we attract staff from countries such as Germany, Switzerland and Nigeria, and all areas of the United States."

The build-out for the 27,000 square-foot facility was largely funded by Connecticut Innovations, one of the State's leading investors in high technology. Rib-X management worked directly with the owner and manager of The George Street Technology Center, Winstanley Enterprises, LLC of Concord, Massachusetts, in securing the space and negotiating the lease. The George Street Technology Center is home to numerous other biotechnology companies.

About Rib-X Pharmaceuticals

Rib-X Pharmaceuticals is a small molecule drug discovery company focused on the structure-based design of new classes of anti-infective agents. The Company's drug discovery strategy is focused on the exploitation of its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis, and to which many known antibiotics bind. The 50S is the target for many clinically important classes of antibiotics, including those used to treat both community-acquired and hospital pathogens. The Company's integrated research approach combines state of the art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allowing for the rapid synthesis of new agents, which avoid typical antibiotic resistance mechanisms. Utilizing these tools, Rib-X has what amounts to a map of the 50S subunit of the ribosome. The Company is utilizing this advantage in the optimization of leads and the creation of new classes of antibiotics.

For more information on the Rib-X mission, please visit the Company website.

Investor Relations		Media Contact
Matthew Duch		Irma Gomez-Dib
FD		FD
88 Pine Street, 32nd Floor		88 Pine Street, 32nd Floor
New York NY 10005		New York NY 10005
212.850.5758		212.850.5761
matthew.duch@fd.com		irma.gomez-dib@fd.com